Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2007

View Archived Issues

Experiments reveal characteristics of GA2-50, a possible treatment for cocaine abuse

Less toxicity seen with ISA-247 than with ciclosporin in vitro

Natural products in dermatology

UC Davis and M.I.N.D. Institute awarded grant for Fragile X research / News in Context

Palatin reacquires full rights to bremelanotide program

BrainStorm Cell Therapeutics takes initial steps toward FDA IND submission

Ownership of GI motility dysfunction program and TD-1792 retained by Theravance

Data from Accentia's phase III trial suggest fungal-induced inflammation as cause of CS

FDA grants Bioniche SPA for phase III study of MCC for bladder cancer

Update on Welichem's phase I trials of WBI-1001 for psoriasis

FDA extends review period of sNDA of Frova for short-term prevention of menstrual migraine

Ariad and FDA agree on SPA for phase III trial of deforolimus for metastatic sarcomas

Positive results for Moberg Derma's phase II trial of K-301 for seborrheic dermatitis

Basilea submits MAA for oral alitretinoin for chronic hand eczema in Europe

Novel therapeutic options for obesity and metabolic diseases described in recent patents

Wyeth and Progenics begin clinical trials of subcutaneous and intravenous methylnaltrexone

Novel agents for cardiovascular disorders disclosed in recent Takeda and Pfizer patents

Novel treatments for musculoskeletal and connective tissue disorders claimed in recent patents

Indolent NHL subject of Cell Therapeutics' phase III trial with pixantrone

EDSMB encourages continuation of phase III trial with Arena's lorcaserin

Promising phase II results with TPI-1020 support potential COPD trial

Wake-promoting profile of a novel histamine H3 antagonist

Auxilium begins dosing patients in two phase III trials of Xiaflex

Merck & Co. completes acquisition of NovaCardia

Astellas Pharma evaluates ASP-0485 for new indication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 22, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
Saniona reports preclinical data for SAN-2668
BioWorld Science
Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...
CC-3 antibody shows antitumoral activity in penile cancer
BioWorld Science
Advanced penile cancer (PeCa) is a rare cancer affecting the genitourinary tract with a 5-year survival rate of about 10% when metastatic. First-line therapies...